# EDGAR Filing Document

**Accession Number:** 0001689394
**File Stem:** 0001493152-26-000691
**Filing Date:** 2026-1
**Character Count:** 6234
**Document Hash:** 2c15bbe78c967b72d3e217571e86583b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-000691.hdr.sgml**: 20260106

**ACCESSION NUMBER**: 0001493152-26-000691

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260106

**DATE AS OF CHANGE**: 20260106

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Anixa Biosciences Inc
- **CENTRAL INDEX KEY:** 0000715446
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 112622630
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-36989
- **FILM NUMBER:** 26513551

**BUSINESS ADDRESS:**
- **STREET 1:** 3150 ALMADEN EXPRESSWAY, SUITE 250
- **CITY:** SAN JOSE
- **STATE:** CA
- **ZIP:** 95118
- **BUSINESS PHONE:** 408-708-9808

**MAIL ADDRESS:**
- **STREET 1:** 3150 ALMADEN EXPRESSWAY, SUITE 250
- **CITY:** SAN JOSE
- **STATE:** CA
- **ZIP:** 95118

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ITUS Corp
- **DATE OF NAME CHANGE:** 20140902

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** COPYTELE INC
- **DATE OF NAME CHANGE:** 19920703
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Catelani Michael
- **CENTRAL INDEX KEY:** 0001689394

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 12100 WILSHIRE BOULEVARD
- **STREET 2:** SUITE 1275
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90025

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Catelini Michael
- **DATE OF NAME CHANGE:** 20161104

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Anixa Biosciences, Inc.**

*(Name of Issuer)*

**Common Stock**

*(Title of Class of Securities)*

**03528H109**

*(CUSIP Number)*

**Michael Catelani**<br>c/o Anixa Biosciences, Inc.,<br>3150 Almaden Expressway, Suite 250<br>San Jose CA 95118<br>408-708-9808

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**01/05/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **03528H109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Michael Catelani** | Name of reporting person<br>**Michael Catelani** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2468103.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2468103.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2468103.00** | Aggregate amount beneficially owned by each reporting person<br>**2468103.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.0%** | Percent of class represented by amount in Row (11)<br>**7.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock

**(b) Name of Issuer:**
Anixa Biosciences, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118

**Item 5. Interest in Securities of the Issuer**

**(a)**
7.0%

**(b)**
2,468,103 shares, consisting of: (i) 44,500 shares of common stock held directly and (ii) 2,423,603 shares of common stock issuable upon exercise of stock options held directly by Reporting Person and exercisable within 60 days.

**(c)**
As of the date hereof, Mr. Catelani beneficially owns 2,468,103 shares of the Issuer, consisting of 44,500 shares of common stock held directly and 2,423,603 shares of common stock issuable upon exercise of stock options held directly and exercisable within 60 days. Such shares represent a total of 7.0% of the Issuer's outstanding shares of common stock, an increase from the 5.25% reported on Mr. Catelani's Schedule 13D. The change in ownership is the result of market purchases, the vesting of previously outstanding stock options and a change in the number of stock options that are not yet exercisable but will be exercisable within 60 days. The triggering event for this filing was the granting on January 5, 2026 of a stock option to Mr. Catelani to purchase up to 175,000 shares of common stock at a price of $3.18 per share.

Mr. Catelani has the sole power to vote or direct the vote of, and to dispose or direct the disposition of, the entirety of the number of shares indicated immediately above.  There are no other persons known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Michael Catelani

**Signature:** /s/ Michael Catelani

**Name/Title:** Michael Catelani

**Date:** 01/06/2026